



The Medicines Patent Pool Foundation

Resolution of the Governance Board

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) and members of the Scientific Advisory Panel and Community Advisory Panel for their report assessing the final results of negotiations between MPP (as the implementing partner of Covid-19 Technology Access Pool (C-TAP) at World Health Organization) and Medigen Vaccine Biologics Corporation (Medigen) on a licence agreement (Agreement) for a Covid-19 vaccine related technology. The Board has reviewed the EAG report and the proposed Agreement between MPP and Medigen. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes, and that the Agreement represents an improvement over the status quo.

Therefore, the Board requests the Executive Director to finalise and sign the necessary documents in relation to this C-TAP licence with Medigen to formalise the collaboration.